Aurinia Pharmaceuticals Inc.: Business Overview, Financials & Competitive Analysis
Aurinia Pharmaceuticals Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Aurinia demonstrates strong profitability and LUPKYNIS adoption momentum with manageable risk through international partnerships, but single-product concentration limits upside. Net income jumped to $287.2M on $283.1M revenue as LUPKYNIS sales grew 25%. Cash from operating activities jumped to $135.7 million, supporting the quality of results. Strong commercial execution and.
What is Aurinia Pharmaceuticals Inc.'s industry? Aurinia Pharmaceuticals Inc. (auriniapharma.com) operates in Biopharmaceutical / Specialty Pharmaceuticals. AskCyborg classifies Aurinia Pharmaceuticals Inc. under Biopharmaceutical / Specialty Pharmaceuticals in its company registry.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company's lead commercial product is LUPKYNIS (v...
Cyborg Score thesis
Aurinia demonstrates strong profitability and LUPKYNIS adoption momentum with manageable risk through international partnerships,...
Read the full analyst-debate transcript →Get the Latest Aurinia Pharmaceuticals Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAurinia Pharmaceuticals Inc. Overview
Pro stress-test →Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company's lead commercial product is LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, a severe complication of systemic lupus erythematosus. Total revenue reached $283.1 million for 2025, up 20% from 2024, with LUPKYNIS net product sales rising 25% to $271.3 million.
Strategic Profile
Pro stress-test →The company moved to solid profitability, with 2025 net income of $287.2 million versus $5.8 million a year earlier. A collaboration with Otsuka Pharmaceutical Co., Ltd. has allowed Aurinia to extend its market presence to Japan, the E.U., the U.K., and Switzerland, diversifying revenue streams and mitigating single-market risk. However, Aurinia's dependence on LUPKYNIS for the majority of its revenue exposes the company to market volatility and competitive pressures, as any challenges could have a disproportionate impact on financial performance.
Competitive Landscape
Pro stress-test →LUPKYNIS is the first FDA-approved oral therapy for active lupus nephritis. Aurinia competes in the specialty immunosuppressant and lupus nephritis treatment space against traditional therapies and other biopharmaceutical companies. The first-mover advantage in oral lupus nephritis treatment provides differentiation, though competitive threats from other autoimmune disease therapies exist.
Industry Context
Aurinia Pharmaceuticals Inc. operates in Biopharmaceutical / Specialty Pharmaceuticals.
Key facts
Founded: 1993 · Headquarters: Edmonton, Canada · Revenue: $283.1M (2025) · Market cap: $1.9B